Oil

Bayer to work with Foundation Medicine on selecting cancer patients

Credit: REUTERS/WOLFGANG RATTAY

Bayer struck a collaboration deal with Roche's Foundation Medicine Inc. to develop test kits for genetic sequencing of tumour cells to identify cancer patients that benefit from Bayer's Vitrakvi drug.

FRANKFURT, May 29 (Reuters) - Bayer BAYGn.DE struck a collaboration deal with Roche's ROG.S Foundation Medicine Inc. to develop test kits for genetic sequencing of tumour cells to identify cancer patients that benefit from Bayer's Vitrakvi drug.

Vitrakvi, which Bayer acquired from Eli Lilly's LLY.N Loxo Oncology, has been shown to shrink tumours in about 1 percent of patients across a range 24 different cancer types. Identifying those patients requires advanced genetic diagnostic tools.

(Reporting by Ludwig Burger Editing by Thomas Seythal)

((ludwig.burger@thomsonreuters.com; +49 69 7565 1311; Reuters Messaging: ludwig.burger.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Renewable Energy

Latest Commodities Videos

    #TradeTalks: The methodology behind the Nasdaq Veles California Water Index and how to hedge water risk

    Nasdaq Global Indexes Head of Product Development Patrick Wolf and WestWater Research Principal Matthew Payne join Jill Malandrino on #TradeTalks​ to discuss the methodology behind the Nasdaq Veles California Water Index and how to hedge water risk.

    Apr 7, 2021

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More